Disease, Hodgkin Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00430846 -
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT00649584 -
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
|
Phase 1 | |
| Completed |
NCT00947856 -
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
|
Phase 2 | |
| Completed |
NCT01060904 -
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
|
Phase 1 | |
| Completed |
NCT01026233 -
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
|
Phase 1 | |
| Completed |
NCT00848926 -
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT01026415 -
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
|
Phase 1 | |
| No longer available |
NCT01196208 -
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
|